A randomized, double-blind controlled trial for sanzihuangshi pill in the treatment of relatively low-risk myelodysplastic syndromes

Phase 1

• Conditions: Myelodysplastic syndrome

• Registration Number: ITMCTR2000003808
• Lead Sponsor: Shanghai Municipal Hospital of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1) Aged 18-75 years old;
2) Meet MDS diagnostic criteria for low and medium risk I in western medicine;
3) It meets the diagnostic criteria of TCM syndromes and is determined by the syndrome differentiation of two senior TCM hematopathy experts;

Exclusion Criteria

1) Secondary MDS;
2) Patients with other blood or non-blood system tumors;
3) Patients with more serious organic diseases such as heart, liver and kidney;
4) Patients during pregnancy or lactation;
5) People with mental illness;
6) Patients with Class A and B infectious diseases;
7) 5q - Patients

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
blood routine test;